A Phase I/II Open-Label, Safety And Preliminary Efficacy Study Of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors (NSCLC, RCC, Bladder, Breast triple negative) Monika Chaudhry | June 19, 2021
